NKGen Biotech develops clinical-stage natural killer cell therapeutics, with news centered on troculeucel, its patient-specific, ex vivo expanded autologous NK cell immunotherapy candidate also known as SNK01. Company updates commonly address Alzheimer’s disease, frontotemporal dementia and cancer development, including conference presentations, clinical and biomarker analyses, mechanistic data and regulatory naming for the program.
Recurring disclosures also cover NKGen’s OTC quotation and trading status, capital-market communications, scientific advisory activity and its majority-owned Korean affiliate, NKGen Biotech Korea Co., Ltd., which develops NK cell therapies and commercializes bioreagents and immunodiagnostic technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.